This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thottassery, J. V. Articles by Parker, W. B. Search for Related Content PubMed PubMed Citation Articles by Thottassery, J. V. Articles by Parker, W. B.

¹ Department of Biochemistry and Molecular Biology, Drug Discovery Division, Southern Research Institute and ² University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama

Requests for reprints: Jaideep V. Thottassery, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205. Phone: 205-581-2846; Fax: 205-581-2877. E-mail: Thottassery{at}sri.org

Nucleoside anticancer drugs like gemcitabine (2'-deoxy-2',2'-difluorocytidine) are potent inducers of p53, and ectopic expression of wild-type p53 sensitizes cells to these agents. However, it is also known that nucleosides are efficient activators of apoptosis in tumor cells that do not express a functional p53. To clarify this issue, we examined the effects of gemcitabine and 4'-thio-ß-D-arabinofuranosylcytosine (T-ara-C) on p73, a structural and functional homologue of p53, whose activation could also account for nucleoside-induced apoptosis because no functionally significant mutations of p73 have been reported in cancers. Acute treatment of HCT 116 colon carcinoma cells with gemcitabine or T-ara-C induced marked cytotoxicity and cleavage of caspase-3 and poly(ADP-ribose) polymerase. T-ara-C and gemcitabine markedly induced p53 accumulation as well as increased levels of phospho-p53 (Ser15/Ser20/Ser46) and induced its binding to a consensus p53 response element. Despite robust activation of p53 by T-ara-C and gemcitabine, we found that wild-type and p53–/– HCT 116 cells exhibited almost equivalent sensitivity towards these nucleosides. Examination of p73 revealed that T-ara-C and gemcitabine markedly increased p73 protein levels and p73 DNA-binding activities in both p53–/– and wild-type cells. Furthermore, T-ara-C- and gemcitabine-induced increases in p73 levels occur due to a decrease in p73 protein turnover. RNA interference studies show that nucleoside-induced p73 increases are independent of c-Abl, a nucleoside-activated kinase recently implicated in p73 stabilization. HCT 116 lines, wherein the downstream p53/p73 targets Bax and PUMA (p53 up-regulated modulator of apoptosis) were deleted, were less sensitive to T-ara-C and gemcitabine. Together, these studies indicate that c-Abl-independent p73 stabilization pathways could account for the p53-independent mechanisms in nucleoside-induced apoptosis. [Mol Cancer Ther 2006;5(2):400–10]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

³ Thottassery et al., unpublished studies.

Received 10/ 6/05; revised 11/29/05; accepted 12/16/05.

This article has been cited by other articles:

				M. L. Clarke, V. L. Damaraju, J. Zhang, D. Mowles, T. Tackaberry, T. Lang, K. M. Smith, J. D. Young, B. Tomkinson, and C. E. Cass The Role of Human Nucleoside Transporters in Cellular Uptake of 4'-Thio-beta-D-arabinofuranosylcytosine and beta-D-Arabinosylcytosine Mol. Pharmacol., July 1, 2006; 70(1): 303 - 310. [Abstract] [Full Text] [PDF]